Results - Announcements
Emcure Pharmaceuticals Ltd share price inched up 0.77% to Rs 1882.5 after the company's net profit rose by 11.14% to Rs 325.07 crore, while revenue from operations improved marginally 9.30% to Rs 2820.47 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 5.09%. It has marginally improved by 2.16% over last one week and moved up slightly by 0.86% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has inched up 0.39% and 3.89% in the same period respectively.
Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 445.85 crore in Q3 FY26, expanding by 30.59% year-on-year, and heading higher 13.30% quarter-on-quarter. EBITDA came in at Rs 585 crore, rallying 23.76% YoY and advancing by 10.21% sequentially.
Total expenses saw a slight increase of 8.57% to Rs 2342.3 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 642.13 crore, witnessing a sharp rise of 33.46% YoY, while employee benefits expense was at Rs 434.71 crore, inching up 6.16% YoY.
For the TTM ended FY26, revenue from operations rose 16.56% to Rs 9203.54 crore, while net profit soared by 33.05% to Rs 941.27 crore, compared to previous TTM. EBITDA jumped by 143704% to Rs 1851.89 crore, and PBT jumped 32.51% to Rs 1287.14 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 943.55 crore in FY26, as against Rs 851.71 crore in FY25.
Emcure Pharmaceuticals Ltd rallied 42.03% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 9.87% during the same period.